Skip to search formSkip to main contentSkip to account menu

LY2334737

Known as: Gemcitabine Prodrug LY2334737 
An orally available valproic acid prodrug of gemcitabine, a broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity… 
National Institutes of Health

Related topics

Related topics

7 relations
DNA Synthesis InhibitionNCIt Antineoplastic Agent TerminologyNucleotide BiosynthesisPositive Regulation of Apoptosis

Broader (1)

Deoxyuridine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors
PurposeThis Phase 1 study aimed to determine the recommended Phase 2 dose of LY2334737, an oral gemcitabine prodrug, when… 
2013
2013
Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts
LY2334737, an oral prodrug of gemcitabine, is cleaved in vivo, releasing gemcitabine and valproic acid. Oral dosing of mice… 
2013
2013
High sensitive assay employing column switching chromatography to enable simultaneous quantification of an amide prodrug of gemcitabine (LY2334737), gemcitabine, and its metabolite dFdU in human…
2012
2012
Phase I and pharmacokinetic (PK)/pharmacodynamic (PD) study of LY2334737, an oral gemcitabine prodrug, in patients (pts) with advanced solid tumors.
2554 Background: LY2334737 is a valproic acid-bound carboxylesterase-substrate prodrug of gemcitabine that can be given orally… 
2012
2012
Novel agents and new combination treatments on phase I studies on solid tumors and pancreatic cancer.
Pancreatic cancer is a relatively rare malignancy with a very aggressive natural course, not restrained by the existing current… 
2012
2012
Abstract 4377: Metronomic oral prodrug of gemcitabine (LY2334737) causes antitumor effects with concomitant increase in intratumoral blood flow
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Metronomic chemotherapy is the regular… 
2011
2011
Abstract 2981: Carboxylesterase 2 hydrolyzes a gemcitabine prodrug (LY2334737) and provides a patient tailoring biomarker
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL LY2334737 (LY) is a prodrug analog of gemcitabine with… 
2009
2009
Development of LY2334737, an oral gemcitabine prodrug for continuous administration. Perspectives for the therapy of mature T-cell and NK-cell lymphomas
Gemcitabine (Gemzar) is a fluorinated pyrimidine nucleoside analogue that demonstrated a high schedule-dependency during its… 
2009
2009
Phase I study of oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients (pts) with advanced solid tumors.
2576 Background: LY2334737 (LY) is an orally available valproic acid prodrug of gemcitabine that was developed to overcome the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)